Showing 4011-4020 of 9741 results for "".
- Lilly's Baricitinib Performs Well in Phase 2 AD Studyhttps://practicaldermatology.com/news/lillys-baricitinib-performs-well-in-phase-2-ad-study/2458052/Lilly’s experimental JAK inhibitor Baricitinib in combination with a mid-potency topical corticosteroid (TCS) significantly improved the signs and symptoms of moderate-to-severe atopic dermatitis (AD) compared to TCS alone, with improvements seen as earl
- Kyocera Begins Research in AI-based Image Recognition to Help Diagnose Skin Diseases and Cancers Via Smartphonehttps://practicaldermatology.com/news/kyocera-begind-research-in-ai-based-image-recognition-to-help-diagnose-skin-diseases-and-cancers-via-smartphone/2458070/Kyocera Corporation is partnering with the University of Tsukuba to develop Artificial Intelligence (AI)-based image recognition for eHealth applications to diagnose melanoma and other skin diseases by analyzing digital images of a patient’s skin.
- Simulation Techniques Help Medical Students Empathize with Melanoma Patientshttps://practicaldermatology.com/news/simulation-techniques-help-medical-students-empathize-with-melanoma-patients/2458110/Simulation techniques can allow doctors to experience what it feels like to be a melanoma patient. The study, which is led by Queen’s University in Belfast collaboration with researchers from the University of Huddersfield and University College Dublin, appears in the
- HydroLotion Scores National Eczema Association Seal of Acceptancehttps://practicaldermatology.com/news/hydrolotion-scores-national-eczema-association-seal-of-acceptance/2458138/Theraplex Company’s HydroLotion Daily Skin Moisturizer now has the National Eczema Association (NEA) Seal of Acceptance. The light-weight moisturizer for the face and body is hypoallergenic, noncomedogenic, and free of fragrances, preservatives
- Stratpharma AG's Wound Care Products Come to the UShttps://practicaldermatology.com/news/stratpharma-ags-wound-care-products-come-to-the-us/2458148/Stratpharma’s wound care and scar management portfolio is now available in the US, according to Stratpharma Inc. USA, a U.S. subsidiary of Stratpharma AG, the Swiss company. The portfolio include
- Cynosure's SculpSure Cleared for Back, Inner and Outer Thighshttps://practicaldermatology.com/news/cynosures-sculpsure-cleared-for-back-inner-and-outer-thighs/2458155/The U.S. Food and Drug Administration (FDA) granted an expanded clearance for Cynosure's SculpSure to treat the back and inner and outer thighs. The SculpSure treatment is already FDA-cleared for treatment of the abdomen an
- EMA Grants Orphan Status to Tarix's EB Candidiatehttps://practicaldermatology.com/news/ema-grants-orphan-status-to-tarixs-eb-candidiate/2458160/The European Medicines Agency (EMA) granted Orphan Drug status to Tarix Orphan LLC’s lead compound, TXA127, for the treatment of epidermolysis bullosa (EB). TXA127 is a pharmaceutical grade formulation of the naturally occurring peptide
- Sensus Healthcare Wins Technology Award from Greater Miami Chamber of Commercehttps://practicaldermatology.com/news/sensus-healthcare-wins-technology-award-from-greater-miami-chamber-of-commerce/2458174/Sensus Healthcare, Inc. was awarded the 2017 Technology Leader of the Year for the Disruptive Technology by The Greater Miami Chamber of Commerce. Sensus provides a non-invasive, cost-effective treatment for NMSC and keloids using the company’s proprietary,
- Sun Pharma Announces US FDA Filing Acceptance of Biologics License Application For Tildrakizumabhttps://practicaldermatology.com/news/sun-pharma-announces-us-fda-filing-acceptance-of-biologics-license-application-for-tildrakizumab/2458175/The U.S. Food and Drug Administration (FDA) has accepted the Biologics License Application (BLA) for Sun Pharma’s tildrakizumab, an investigational IL-23p19 inhibitor being evaluated for the treatment of moderate-to-severe plaque psoriasis. The
- Non-Invasive Pigmented Lesion Assay Almost Doubles Biopsy Specificityhttps://practicaldermatology.com/news/use-of-non-invasive-pigmented-lesion-assay-almost-doubles-biopsy-specificity/2458209/Dermatologists who incorporate Dermtech’s noninvasive pigmented lesion assay will biopsy fewer benign pigmented skin lesions and miss fewer melanomas, according to a new study in JAMA Dermatology